Gleevec Articles
FDA approves three Takeda diabetes drugs; expands use of Novartis' Gleevec and Pfizer's Prevnar 13
28 January 2013
Small-molecule cancer drug revenues will reach $32.7 billion in 2016, says Visiongain
9 January 2013
Overview of Novartis' patent losses from GlobalData
11 October 2012
More news for ASH meeting
13 December 2011
Novartis cancer drug imatinib shows efficacy in PAH
26 September 2011
Novartis’ Gleevec shows promise for treating scleroderma
29 March 2011
UK’s NICE gives final “no” to NHS use of Novartis cancer drug Glivec; Novartis now holds 77% of Alcon
26 August 2010
UK’s NICE “not minded” to recommend Novartis’ Glivec/Gleevec for GIST patients at risk of recurrence after surgery
24 March 2010
Novartis’ Tasigna gets FDA priority review for early-stage CML and Gilenia for MS; also OK for meningitis vaccine Menveo
22 February 2010
Prioritized pipeline at “new” Pfizer marks important milestone for the company’s R&D organization
28 January 2010
Novartis posts 50% 4th-qtr 2009 profits rise and promotes drugs chief Jimenez to CEO; other top changes
26 January 2010
Ambit sells rights for FLT3 Kinase inhibitors to Japan’s Astellas for up to $390 million
18 December 2009
Novartis aims to hold global position in oncology, with new drugs and indications, R&D meeting told
9 December 2009
FDA grants full approval to B-MS' Sprycel
27 May 2009
Novartis' 1st-qtr 2009 results boosted by new products
24 April 2009
Afinitor cleared in USA for advanced RCC
1 April 2009
China
9 March 2009
FDA approves Novartis' Gleevec for GIST
12 January 2009
ASH hears strong data on Novartis
22 December 2008
Tasigna achieves rapid response in CML Ph+
15 December 2008
Novartis lines up aliskiren combos and cancer drugs to deal with Diovan's 2012 patent loss
24 November 2008
CytRx reports strong early results for CML drug
17 November 2008
Novartis profit up 32% in 3rd qtr
27 October 2008
Novartis PAH Glivec trial misses Ph II endpoint
13 October 2008
India govt "considering" bulk drug deals
28 July 2008
Thai dispute over PReMA member for GPO board
5 May 2008
India NGOs at war with cancer drug patents
7 April 2008
Foreign groups try to stop Thailand CL climbdown
3 March 2008
Thailand Health Ministry change could mean fewer CLs
18 February 2008
Wales' drug authority recommends Sprycel
28 January 2008
India's drugmakers apply for IP protection
24 December 2007
Sanofi invests $25.4M in Goa R&D center
10 December 2007
US challenge for Glivec "could affect India case"
3 December 2007
UPDATE: Thailand negotiations on drug prices continue
29 October 2007
Thailand negotiations on drug prices continue
29 October 2007
CORRECTION: Compromise offer for India Glivec patent case
15 October 2007
Compromise offer for India Glivec patent case
15 October 2007
More compulsory drug licenses for Thailand
1 October 2007
Novartis patent case: Indian govt asks for delay
17 September 2007
Indian patent case driving R&D to China
10 September 2007
Novartis' India patent case adjourned
20 August 2007
UPDATE: Novartis loses India patent law challenge, no appeal planned, Glivec ruling awaited
13 August 2007
Novartis loses India patent law challenge
13 August 2007
Bias concern of Novartis' patent law suit in India
30 July 2007
Novartis' India trial continues over Glivec patent
16 July 2007
Novartis challenges member of IPAB
25 June 2007
SMC approves S-P's Remicade in psoriasis
21 May 2007
Novartis' 1st-qtr 2007 profit up 11% to $2.17B on strong sales of cancer drugs and Diovan
30 April 2007
ChemGenex completes A$21M financing
9 April 2007
India patent law dispute spreads
2 April 2007
Expert group warns India's govt on patents
19 February 2007
Thailand's "patent busting" goes ahead
7 February 2007
Novartis patent law challenge in India
5 February 2007
Diovan, Glivec and generics drive Novartis growth in 2006
22 January 2007
Canada: new formulary for new year - Ontario introducing reform
15 January 2007
Novartis resists more NGO pressure on Glivec
4 December 2006
B-MS' Sprycel approved for resistant CML
27 November 2006
Novartis sees 16% sales jump in first three qtrs of 2006 beating consensus estimates
30 October 2006
Pfizer's Sutent effective against GIST
16 October 2006
Sprycel gets expedited approval for CML
10 July 2006
Genzyme debut Gleevec resistance test
13 February 2006
Novartis sees strong performance with record results in 2005
30 January 2006
Leading UK MP to raise "missing patients" with Health Minister
19 December 2005
ChemGenex/Stragen sign deal for Ceflatonin
1 August 2005
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
